Form D · Biotechnology

NexImmune, Inc.

Gaithersburg, MD · CIK 0001538210

Offering snapshot reported Feb 22, 2019 · SEC filing

Reported sold
$7.77M
Offering amount: $10M
Investors reported
42
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 8, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 22, 2019Initial$7,767,293No comparison42SEC filing
Feb 1, 2018Initial$21,730,000No comparison69SEC filing
Feb 13, 2015Initial$1,962,000No comparison4SEC filing
Jul 25, 2014Initial$3,000,000No comparison3SEC filing
Dec 27, 2013Initial$250,000No comparison1SEC filing
Feb 3, 2012Initial$1,000No comparison9SEC filing
Feb 3, 2012Initial$287,500No comparison11SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-333353

Source: Form D, filed Feb 22, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
James Barrett Director
Timothy Bertram Director
Alain Cappeluti Executive
Slain Cappeluti Director, Executive
Scott Carmer Director, Executive
Kenneth Carter Director, Executive
Paul D'angio Director
Janis Naeve Director
Alan Roemer Director
Jonathan Schneck Director
Robert Spiegel Director
Bing Yao Director
Tony Yao Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
9119 Gaither Road
Gaithersburg, MD, 20877